Crypto market betas: the limits of predictability and hedging by Jan Sila, Michael Mark, Ladislav Kristoufek, Thomas A. Weber

Get full text

A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland by Tämer El Saadany, Judith Lupatsch, Michael Mark, Michaela Barbier, Tarun Mehra, Matthias Schwenkglenks, Roger von Moos

Get full text

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment by Sabine Schmid, MD, Lisa Holer, MSc, Katrin Gysel, MSc, Kira-Lee Koster, MD, Sacha I. Rothschild, MD, Laura A. Boos, MD, Lorenz Frehner, MD, Sabine Cardoso Almeida, MD, Christian Britschgi, MD, PhD, Yannis Metaxas, MD, Michael Mark, MD, Patrizia Froesch, MD, Wolf-Dieter Janthur, MD, Anna Allemann, MD, Christine Waibel, MD, Catherine Von der Mühll-Schill, MD, Martin Früh, MD, Laetitia A. Mauti, MD, PhD

Get full text

Outcomes in Patients With Resectable Stage III NSCLC Who Did Not Have Definitive Surgery After Neoadjuvant Treatment—A Retrospective Analysis of the SAKK Trials 16/96, 16/00, 16/01... by Sabine Raimann, MD, Sämi Schär, PhD, Stefanie Hayoz, PhD, Matthias Guckenberger, MD, Tobias Finazzi, MD, PhD, Isabelle Opitz, MD, Sabine Schmid, MD, Michael Mark, MD, Alfredo Addeo, MD, Laetitia A. Mauti, MD, PhD, Daniel C. Betticher, MD, Hans-Beat Ris, MD, Roger Stupp, MD, Alessandra Curioni-Fontecedro, MD, Solange Peters, MD, PhD, Martin Früh, MD, Sacha I. Rothschild, MD, PhD, Miklos Pless, MD, David König, MD

Get full text